Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 29

Results For "company"

4095 News Found

Cipla reports FY25 PAT higher 28.4% at Rs. 5,273 Cr
News | May 14, 2025

Cipla reports FY25 PAT higher 28.4% at Rs. 5,273 Cr

The company reported 30.1% jump in Q4 FY25 PAT at Rs. 1,222 crore


GlaxoSmithKline Pharmaceuticals posts FY25 PAT at Rs. 915 Cr
News | May 14, 2025

GlaxoSmithKline Pharmaceuticals posts FY25 PAT at Rs. 915 Cr

The Board of Directors of the company recommends a final dividend of Rs. 42 per equity share for the 12 months period ended March 31, 2025


Biocon Q4 FY25 consolidated PAT jumps 153% to Rs. 344 Cr
News | May 14, 2025

Biocon Q4 FY25 consolidated PAT jumps 153% to Rs. 344 Cr

For the full financial year FY25, revenue from operations grew 9 per cent to Rs. 11,537.8 crore, compared to Rs. 10,588 crore in FY24.


Bayer confirms 2025 targets after solid start to the year
News | May 14, 2025

Bayer confirms 2025 targets after solid start to the year

EBITDA before special items decreases to €4.08 billion (7.4%)


Sai Life Sciences FY25 PAT higher by 105% to Rs. 170 Cr
News | May 14, 2025

Sai Life Sciences FY25 PAT higher by 105% to Rs. 170 Cr

PAT stood at Rs. 88 crore for Q4 FY25 as compared to Rs. 56 crore in Q4FY24, an increase of 57%


Caplin Steriles gets USFDA approval for Haloperidol Decanoate Injection
Drug Approval | May 14, 2025

Caplin Steriles gets USFDA approval for Haloperidol Decanoate Injection

Haloperidol Decanoate Injection indicated for the treatment of patients with schizophrenia who require prolonged parenteral antipsychotic therapy


Artemis Medicare Services posts Q4 FY25 consolidated PAT at Rs. 23.02 Cr
News | May 13, 2025

Artemis Medicare Services posts Q4 FY25 consolidated PAT at Rs. 23.02 Cr

The company has posted net profit of Rs. 82.62 crores for the Financial Year ended March 31, 2025


Krsnaa Diagnostics posts Q4 FY25 consolidated PAT at Rs. 20.67 Cr
News | May 13, 2025

Krsnaa Diagnostics posts Q4 FY25 consolidated PAT at Rs. 20.67 Cr

The company has posted net profit of Rs. 77.60 crores for the Financial Year ended March 31, 2025


Bliss GVS Pharma posts Q4 FY25 consolidated PAT at Rs. 15.53 Cr
News | May 13, 2025

Bliss GVS Pharma posts Q4 FY25 consolidated PAT at Rs. 15.53 Cr

The company has posted net profit of Rs. 84.29 crores for the Financial Year ended March 31, 2025


Morepen Laboratories reports Q4 FY25 consolidated PAT at Rs. 20.31 Cr
News | May 13, 2025

Morepen Laboratories reports Q4 FY25 consolidated PAT at Rs. 20.31 Cr

The company has posted net profit of Rs. 118.01 crores for the Financial Year ended March 31, 2025